Regeneron

Founded in 1988, the biotechnology company with headquarters in Tarrytown, New York, operates in several key business segments including Ophthalmology, Oncology, Inflammation, Genetic Diseases, Infectious Diseases, and Neurology. Among its most notable brands are EYLEA (aflibercept), used to treat wet age-related macular degeneration and other eye diseases; Dupixent (dupilumab), for atopic dermatitis, asthma, and nasal polyps; Praluent (alirocumab), a medication to lower cholesterol; Kevzara (sarilumab), for rheumatoid arthritis; and REGN-COV2 (casirivimab and imdevimab antibody cocktail), for the treatment and prevention of COVID-19. The company's products and services have a major presence in the United States and are sold internationally, reaching markets across Europe, Asia, and Canada. This global availability is facilitated through strategic partnerships and collaborations with other pharmaceutical leaders like Sanofi and Bayer. (Powered by AI)